10.10.23
NEWS & EVENTS
What’s “c/λ” at Accent?
News
9.21.23
Accent Therapeutics Bolsters Leadership Team with Key Executive Hires
4.16.23
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
4.6.23
Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
10.18.21
Ipsen Adds Another Program Into Its Pre-clinical R&D; Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
6.4.20
Accent Therapeutics and AstraZeneca to Discover and Develop Novel Cancer Therapeutics in New Collaboration
4.23.20
Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting Rna-modifying Proteins
9.3.19